GH Research PLC
Close on Oct 19, 2026
- Market cap
- $1.22B
- P/E (TTM)
- –
- Dividend yield
- –
About GH Research
Pharmaceutical Preparations, SIC 2834
GH Research PLC is a clinical-stage biopharmaceutical company that develops novel investigational therapies based on mebufotenin. Its primary product candidates include GH001 and GH002, which are designed to treat medical indications alongside proprietary administration equipment, such as an aerosol delivery device developed for GH001. The company operates without commercial business segments and currently has no approved commercial products. Consequently, it has not yet established a commercial customer base, though its prospective users and end recipients include patients, prescribing medical professionals, and specialized third-party clinics or treatment centers.
The company maintains its corporate headquarters in Dublin, Ireland. Operationally, GH Research conducts clinical trials within Europe and seeks to expand its regulatory and clinical development activities into other jurisdictions, including the United States. It does not own commercial manufacturing infrastructure or distribution facilities, relying instead on external partners, suppliers, and third-party clinical trial centers to support its nonclinical research and clinical development programs.
Summary of the business section of GH Research's latest annual report, written by StockData.
Company profile
Company
- Legal name
- GH Research PLC
- Headquarters
- Dublin 2, L2
- Address
- Joshua Dawson House, Dawson Street D02 RY95
- Phone
- 353 1 437 8334
- Website
- ghres.com
- Employees
- 73, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- L2
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers, Dublin, Ireland
Stock & identifiers
- Ticker
- GHRS
- Exchange
- Nasdaq
- IPO date
- Jun 28, 2021
- Shares outstanding
- 62M, Dec 31, 2025
- Filer category
- Accelerated filer<br>Emerging growth company
- SEC CIK
- 1855129
- CUSIP
- G3855L106
- ISIN
- USG3855L1064
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Aaron Luke Cameron | Chief Operating Officer | – |
| Julie Ryan | VP, Finance | – |
| Velichka Valcheva | Chief Executive Officer | – |
| Magnus Clemensen Halle | Managing Director, Ireland | 118,354 |
| Florian Schonharting | Director | 14,824,419 |
| Dermot John Hanley | Director | 2,432 |
| Michael Forer | Director | 45,509 |
| Duncan Moore | Director | 14,600 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed seventy-three people.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 28, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 22, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |